The comprehensive glycaemic control using the triple combination- Voglibose, Glimepiride, Metformin
Abstract
Diabetes mellitus is one of the most prevalent metabolic diseases in the world. Type 1 diabetes is due to insulin deficiency affecting about 5-10% of the diabetic population, whereas type 2 is most common which occurs mainly due to insulin resistance. Diabetes is one of the leading causes of morbidity and mortality characterized by hyperglycemia that is associated with several complications including neuropathy, nephropathy, heart disease, stroke and vascular diseases
Downloads
References
Ghani U. Re-exploring promising α- glucosidase inhibitors for potential development into oral anti-diabetic drugs: Finding a needle in the haystack. Eur J Med Chem. 2015;103:133-162. doi:10.1016/j.ejmech.2015.08.043
Vijayakumar TM, Jayram J, Meghana Cheekireddy V, Himaja D, Dharma Teja Y, Narayanasamy D. Safety, Efficacy, and Bioavailability of Fixed-Dose Combinations in Type 2 Diabetes Mellitus: A Systematic Updated Review. Curr Ther Res - Clin Exp. 2017;84:4-9. doi:10.1016/j.curtheres.2017.01.005
Chawla G, Chaudhary KK. A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus. Diabetes Metab Syndr Clin Res Rev. 2019;13(3):2001-2008. doi:10.1016/j.dsx.2019.04.035
Choi HK, Oh M, Kim EJ, et al. Pharmacokinetic study of metformin to compare a voglibose/metformin fixed-dose combination with coadministered voglibose and metformin. Int J Clin Pharmacol Ther. 2015;53(2):147-153. doi:10.5414/CP202197
Yu HM, Kim SJ, Chun SW, et al. A comparison study on efficacy, insulin sensitivity, and safety of glimepiride/Metformin fixed-dose combination versus glimepiride single therapy on type 2 diabetes mellitus patients with basal insulin therapy. Diabetes Res Clin Pract. 2019;155:107796. doi:10.1016/j.diabres.2019.107796
Turner RC, Cull CA, Frighi V, Holman RR. The UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005–2012.
Cusi K, Consoli A DR. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1996;81:4059–4067.
Koshiba K, Nomura M, Nakaya Y IS. Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. J Med Invest. 2006;53:87– 94.
Gu N, Kim BH, Rhim HY, et al. Comparison of the bioavailability and tolerability of fixed-dose combination glimepiride/metformin 2/500-mg tablets versus separate tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy Korean volunteers. Clin Ther. 2010;32(7):1408-1418. doi:10.1016/j.clinthera.2010.07.012
Umpierrez G, Issa M VA. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: Results of a randomized clinical trial. Curr Med Res Opin. 2006;22:751–759.
Bennett WL, Maruthur NM, Singh S et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med.2011;154(9):602-613.
McIntosh B, Cameron C, Singh SR et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med. 2011;5(1):e35-e48.
Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427-2443.
Murti K, Sethi MK, Dey A, Lal CS, Pandey K, Das P. Addition of voglibose to glimepiride and metformin have better glucose control in diabetics: A prospective, parallel-group and open-label comparative study. Int J Pharmacol. 2016;12(4):422- 428. doi:10.3923/ijp.2016.422.428
John M, Gopinath D, Kalra S. Triple fixed drug combinations in type 2 diabetes. Indian J Endocrinol Metab. 2015;19(3):311-313. doi:10.4103/2230-8210.152739
